Supply Chain Ecosystem Analysis now part of DBMR Reports
Market Size in USD Billion
| 2024 –2030 | |
|
|
|
| USD 1,019.00 | |
| % | |
|
North America Fecal Occult Blood Tests Market, By Test Type (Lateral Flow Immuno-Fob Test Kits, Immuno-FOB Agglutination Test Kits, Immuno-FOB ELISA Test Kits, Guaiac FOB Stool Test, Flushable Reagent Pad or Tissue, and Others), Application (Colorectal Cancer Screening, Concern for Gastrointestinal Bleeding, Polyps, Diverticulosis, Ulcers, Haemorrhoids, Colitis, Anemia, and Others), End User (Diagnostic Laboratories, Hospitals, Specialty Clinics, and Others), Distribution Channel (Direct Sales, Retail Sales, E-Commerce, and Others), Industry Trends and Forecast to 2030.
Get Exclusive Sample Copy of this Report Here
One of the primary factors driving the growth of the fecal occult blood tests market is the rising cases of colorectal cancer in North America. The continuing clinical trial research being conducted by several companies for better diagnosis leads to market expansion. The market is also influenced by the development of direct-to-consumer laboratory testing and the easy availability of fecal occult immunological test devices in online stores.
Get Exclusive Sample Copy of this Report Here
Get Exclusive Sample Copy of this Report Here
North America fecal occult blood tests market is expected to gain market growth in the forecast period of 2023 to 2030. Data Bridge Market Research analyses that the market is growing with a CAGR of 5.9% in the forecast period of 2023 to 2030 and is expected to reach USD 1,019.00 million by 2030.
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customisable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million
|
|
Segments Covered
|
By Test Type (Lateral Flow Immuno-Fob Test Kits, Immuno-FOB Agglutination Test Kits, Immuno-FOB ELISA Test Kits, Guaiac FOB Stool Test, Flushable Reagent Pad or Tissue, and Others), Application (Colorectal Cancer Screening, Concern for Gastrointestinal Bleeding, Polyps, Diverticulosis, Ulcers, Haemorrhoids, Colitis, Anemia, and Others), End User (Diagnostic Laboratories, Hospitals, Specialty Clinics, and Others), Distribution Channel (Direct Sales, Retail Sales, E-Commerce, and Others)
|
|
Countries Covered
|
U.S., Canada, and Mexico
|
|
Market Players Covered
|
Biopanda Reagents Ltd, HUMASIS.COM, CTK Biotech, Inc., Biohit Oyj, CERTEST BIOTEC, Alfa Scientific Designs, Inc., Cenogenics Corporation, and Jant Pharmacal Corporation., Quidel Corporation, Wondfo., Siemens Healthcare GmbH among others
|
Market Definition
A fecal occult blood test (FOBT) is a diagnostic screening test performed to analyze hidden (occult) blood in stool samples. The fecal occult blood test is also known as stool occult blood, immunoassay FOBT, hemoccult, and IFOBT and guaiac smear test commonly. The test is majorly utilized to screen colon cancer and analyze possible causes of unexplained anemia.
This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
Colorectal cancer is a disease of the colon or rectum, which are parts of the digestive system. Unlike most cancers, colorectal cancer is often preventable with screening & can be treated when detected early. Most cases of colorectal cancer occur in people ages 45 & older. The disease is increasingly affecting younger people due to unhygienic lifestyles & smoking habits. Colorectal cancers may develop without symptoms. The common symptoms may include blood in or on the stool, persistent unusual bowel movements like constipation or diarrhea, stomach pain, aches or cramps that last longer and losing weight for no reason.
Most colorectal cancers start as abnormal tissue growth, called a polyp, inside the colon or rectum. Doctors can detect polyps with the help of screening tests & can remove them from developing into colorectal cancer. Even if it spreads into nearby lymph nodes, chemotherapy & surgical treatments are effective ways to treat colorectal cancer. Research is going on to learn more about this disease and provide more hope to people with all stages of colorectal cancer.
Direct-to-consumer laboratory testing is an effective way for users where they can order their corresponding laboratory tests directly from a lab without any healthcare providers. Nowadays, the healthcare industry is shifting towards direct-to-consumer laboratory testing from physician-based lab testing & hence the demand has increased drastically. Most of the patients are focusing on direct-to-consumer based laboratory tests without going through a lengthy in-clinic process, which is fueling the growth of the fecal occult blood tests market.
For the identification of previously unknown medical disorders, the test results are used. The advancements in the field of direct-to-consumer laboratory testing have become crucial to increase patient engagement for better monitoring & screening of existing health conditions. Hence, it is very important for laboratory professionals to upgrade the devices & instruments used in testing laboratories.
Easy Availability Of Fecal Occult Immunological Test Devices In Online Stores
A fecal occult blood test (FOBT) generally focuses on a stool sample to check for blood. The presence of blood in stool refers that there is bleeding in the digestive tract. The bleeding can be caused by a variety of conditions like Polyps (abnormal growths on the lining of the colon or rectum), Hemorrhoids (swollen veins in the anus or rectum), Diverticulosis (a condition with small pouches in the inside wall of the colon), Ulcers (sores in the lining of the digestive tract), Colitis (a type of inflammatory bowel disease) and Colorectal cancer.
There are a huge number of fecal occult immunological test devices available in the market, and people can buy the kits & devices from various online sites. Hence, it can be a driving factor for the growth of the fecal occult blood tests market.
Opportunities
Increase in screening procedures
Most government agencies and scientific societies recommend cervical, breast, and colorectal screening because of the burden of these cancers, the availability of screening tests, and the proven efficacy of screening in reducing mortality, as well as incidence, for cervical and colorectal cancers.
The European Community recommends the implementation of population-based screening programs for colorectal cancers. This recommendation is supported by many observational studies showing that organized programs effectively reduce mortality and control the inappropriate use of screening tests.
Rising technical advancements
A blood test has always been a technology- and data-dependent field. As data and technology potentially revolutionized diagnostic services and had positioned to partner with patients, families, practitioners, researchers, industry leaders, policymakers, and administrators to ensure that humanistic, high-value, ever-improving precise diagnosis remains the central goal for the future of blood test diagnosis.
The use of fecal occult blood testing has expanded to several indications, even though its primary use is for evaluating an occult source of GI blood loss and for home-based kits in colorectal carcinoma screening. One of the most common clinical uses for the hemoccult is for checking a stool specimen for occult bleeding prior to anticoagulation.
Restraints/Challenges
The fecal occult blood test products bear a high cost and usually cannot be afforded by everyone in general. As technology is getting more advanced day by day & there are a number of test alternatives available in the market. Hence, people prefer cost-effective alternatives for fecal occult blood tests. There are various screening programs that often target people with apparently healthy conditions & the number of people using screening services is usually higher than the true number of patients. The FOBT has advantages over colonoscopy in terms of being less costly and easy to perform.
As most of the fecal occult blood test alternatives are available in the market. Hence, people prefer substitutes with lesser cost & more accurate results. Hence, the change in consumer preference toward cost-effective alternatives may restrain the market growth in the forecast period.
The fecal occult blood test is not always accurate and could show a negative test result when cancer is present and have a false-negative result if cancer or polyps do not bleed.
The test could show a positive result when the person has no cancer (false-positive result) or have bleeding from other sources, such as a stomach ulcer, hemorrhoid, or even blood swallowed from the mouth or nose.
The COVID-19 pandemic had a great impact on the fecal occult blood test industries. Trade groups in colorectal cancer and gastrointestinal bleeding diagnostic products sector claim that the North America supply chain for diagnostic products has been significantly damaged, impacting end-user consumption of the fecal occult blood tests market. Sales of test products in the first quarter of 2020 were significantly delayed due to logistical and transportation issues. On the demand side, the market is increasing as people have to get diagnosed after the lockdown scenario. The situation needs to be taken into consideration, and emergency diagnostics need to be done. Furthermore, on the supply side, the growth of the market is on a negative scale. This is due to the lockdown situations in many countries manufacturing diagnostic, operating and cancer care and fecal occult blood test instruments.
Recent Developments
The North America fecal occult blood tests market is segmented into four notable segments based on test type, application, end user and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Test Type
On the basis of test type, the North America fecal occult blood tests market is segmented into lateral flow immuno-FOB test kits, immuno-FOB agglutination test kits, immuno-FOB ELISA test kits, guaiac FOB stool tests, flushable reagent pad or tissue, and others.
Application
On the basis of application, the North America fecal occult blood tests market is segmented into Colorectal Cancer Screening, Concern for gastrointestinal bleeding, Polyps, Diverticulosis, Ulcers, Haemorrhoids, Colitis, Anemia, and others.
End User
On the basis of end user, the North America fecal occult blood tests market is segmented into diagnostic laboratories, hospitals, specialty clinics, and others.
Distribution Channel
On the basis of distribution channel, the North America fecal occult blood tests market is segmented into direct tender, retail sales, e-commerce, and others.
Get Exclusive Sample Copy of this Report Here
The fecal occult blood tests market is analysed, and market size insights and trends are provided by country, test type, application, end user, distribution channel, as referenced above.
North America fecal occult blood tests market comprises of the countries U.S., Canada, and Mexico.
The U.S. is expected to dominate the North America fecal occult blood tests market due to increasing inclination towards point-of-care diagnostics. An increase in demand for fecal occult blood test products and an increase in research and development activities in the industry are also expected to drive the market in the forecasted period.
The country section of the report also provides individual market impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of North America brands and their challenges faced due to high competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.
The fecal occult blood tests market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, North America presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies focus on the North America fecal occult blood tests market.
Some of the major players operating in this market are Biopanda Reagents Ltd, HUMASIS.COM, CTK Biotech, Inc., Biohit Oyj, CERTEST BIOTEC, Alfa Scientific Designs, Inc., Cenogenics Corporation, and Jant Pharmacal Corporation., Quidel Corporation, Wondfo., Siemens Healthcare GmbH among others.
SKU-
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE SEGMENT LIFELINE CURVE
2.8 MARKET APPLICATION COVERAGE GRID
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER'S 5 FORCES
5 INDUSTRY INSIGHTS
6 REGULATORY FRAMEWORK
6.1 REGULATORY SCENARIO BY U.S. FDA
6.2 REGULATORY SCENARIO IN U.S.
6.3 REGULATORY SCENARIO IN EUROPE
6.4 REGULATORY SCENARIO IN CANADA
6.5 REGULATORY SCENARIO IN AUSTRALIA
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 RISING CASES OF COLORECTAL CANCER NORTH AMERICALY
7.1.2 DEVELOPMENT OF DIRECT-TO-CONSUMER LABORATORY TESTING
7.1.3 EASY AVAILABILITY OF FECAL OCCULT IMMUNOLOGICAL TEST DEVICES IN ONLINE STORES
7.1.4 INCREASING INCLINATION TOWARDS POINT-OF-CARE DIAGNOSTICS
7.2 RESTRAINTS
7.2.1 CHANGE IN CONSUMER PREFERENCE TOWARDS COST-EFFECTIVE ALTERNATIVES
7.2.2 LOW AWARENESS ABOUT FECAL OCCULT BLOOD TESTS IN UNDEVELOPED COUNTRIES
7.3 OPPORTUNITIES
7.3.1 INCREASE IN SCREENING PROCEDURES
7.3.2 RISING TECHNICAL ADVANCEMENTS
7.3.3 STRATEGIC INITIATIVES
7.4 CHALLENGES
7.4.1 LACK OF SKILLED PROFESSIONALS
7.4.2 LOW EFFICIENCY
8 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE
8.1 OVERVIEW
8.2 LATERAL FLOW IMMUNO-FOB TEST KITS
8.3 IMMUNO-FOB AGGLUTINATION TEST KITS
8.4 IMMUNO-FOB ELISA TEST KITS
8.5 GUAIAC FOB STOOL TEST
8.5.1 KITS
8.5.1.1 GUAIAC SLIDES
8.5.1.1.1 25 PACKAGE
8.5.1.1.2 20 PACKAGE
8.5.1.1.3 OTHERS
8.5.1.2 ALPHA GUAIACONIC ACID (GUAIAC) IMPREGNATED PAPER
8.5.1.2.1 SENSITIVITY IS 50NG/ML
8.5.1.2.1.1 25 PACKAGE
8.5.1.2.1.2 20 PACKAGE
8.5.1.2.1.3 OTHERS
8.5.1.2.2 SENSITIVITY IS 75NG/ML
8.5.1.2.2.1 25 PACKAGE
8.5.1.2.2.2 20 PACKAGE
8.5.1.2.2.3 OTHERS
8.5.1.2.3 OTHERS
8.5.1.3 OTHERS
8.5.2 REAGENTS
8.5.2.1 HYDROGEN PEROXIDE
8.5.2.2 OTHERS
8.6 FLUSHABLE REAGENT PAD OR TISSUE
8.7 OTHERS
9 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 COLORECTAL CANCER SCREENING
9.2.1 LATERAL FLOW IMMUNO-FOB TEST KITS
9.2.2 IMMUNO-FOB AGGLUTINATION TEST KITS
9.2.3 IMMUNO-FOB ELISA TEST KITS
9.2.4 GUAIAC FOB STOOL TEST
9.2.5 FLUSHABLE REAGENT PAD OR TISSUE
9.2.6 OTHERS
9.3 CONCERN FOR GASTROINTESTINAL BLEEDING
9.3.1 LATERAL FLOW IMMUNO-FOB TEST KITS
9.3.2 IMMUNO-FOB AGGLUTINATION TEST KITS
9.3.3 IMMUNO-FOB ELISA TEST KITS
9.3.4 GUAIAC FOB STOOL TEST
9.3.5 FLUSHABLE REAGENT PAD OR TISSUE
9.3.6 OTHERS
9.4 POLYPS
9.4.1 LATERAL FLOW IMMUNO-FOB TEST KITS
9.4.2 IMMUNO-FOB AGGLUTINATION TEST KITS
9.4.3 IMMUNO-FOB ELISA TEST KITS
9.4.4 GUAIAC FOB STOOL TEST
9.4.5 FLUSHABLE REAGENT PAD OR TISSUE
9.4.6 OTHERS
9.5 DIVERTICULOSIS
9.5.1 LATERAL FLOW IMMUNO-FOB TEST KITS
9.5.2 IMMUNO-FOB AGGLUTINATION TEST KITS
9.5.3 IMMUNO-FOB ELISA TEST KITS
9.5.4 GUAIAC FOB STOOL TEST
9.5.5 FLUSHABLE REAGENT PAD OR TISSUE
9.5.6 OTHERS
9.6 ULCERS
9.6.1 LATERAL FLOW IMMUNO-FOB TEST KITS
9.6.2 IMMUNO-FOB AGGLUTINATION TEST KITS
9.6.3 IMMUNO-FOB ELISA TEST KITS
9.6.4 GUAIAC FOB STOOL TEST
9.6.5 FLUSHABLE REAGENT PAD OR TISSUE
9.6.6 OTHERS
9.7 HAEMORRHOIDS
9.7.1 LATERAL FLOW IMMUNO-FOB TEST KITS
9.7.2 IMMUNO-FOB AGGLUTINATION TEST KITS
9.7.3 IMMUNO-FOB ELISA TEST KITS
9.7.4 GUAIAC FOB STOOL TEST
9.7.5 FLUSHABLE REAGENT PAD OR TISSUE
9.7.6 OTHERS
9.8 COLITIS
9.8.1 LATERAL FLOW IMMUNO-FOB TEST KITS
9.8.2 IMMUNO-FOB AGGLUTINATION TEST KITS
9.8.3 IMMUNO-FOB ELISA TEST KITS
9.8.4 GUAIAC FOB STOOL TEST
9.8.5 FLUSHABLE REAGENT PAD OR TISSUE
9.8.6 OTHERS
9.9 ANEMIA
9.9.1 LATERAL FLOW IMMUNO-FOB TEST KITS
9.9.2 IMMUNO-FOB AGGLUTINATION TEST KITS
9.9.3 IMMUNO-FOB ELISA TEST KITS
9.9.4 GUAIAC FOB STOOL TEST
9.9.5 FLUSHABLE REAGENT PAD OR TISSUE
9.9.6 OTHERS
9.1 OTHERS
10 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET, BY END USER
10.1 OVERVIEW
10.2 DIAGNOSTIC LABORATORIES
10.3 HOSPITALS
10.4 SPECIALITY CLINICS
10.5 OTHERS
11 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET, BY DISTRIBUTION CHANNEL
11.1 OVERVIEW
11.2 DIRECT TENDER
11.3 RETAIL SALE
11.4 E-COMMERCE
11.5 OTHERS
12 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET, BY REGION
12.1 NORTH AMERICA
12.1.1 U.S.
12.1.2 CANADA
12.1.3 MEXICO
13 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET: COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
14 SWOT ANALYSIS
15 COMPANY PROFILE
15.1 QUIDEL CORPORATION
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.1.5 RECENT DEVELOPMENT
15.2 WONDFO.
15.2.1 COMPANY SNAPSHOT
15.2.2 COMPANY SHARE ANALYSIS
15.2.3 PRODUCT PORTFOLIO
15.2.4 RECENT DEVELOPMENT
15.3 SIEMENS HEALTHCARE GMBH
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 COMPANY SHARE ANALYSIS
15.3.4 RODUCT PORTFOLIO
15.3.5 RECENT DEVELOPMENT
15.4 EIKEN CHEMICAL CO., LTD.
15.4.1 COMPANY SNAPSHOT
15.4.2 REVENUE ANALYSIS
15.4.3 COMPANY SHARE ANALYSIS
15.4.4 PRODUCT PORTFOLIO
15.4.5 RECENT DEVELOPMENT
15.5 BIOHIT OYJ
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 COMPANY SHARE ANALYSIS
15.5.4 PRODUCT PORTFOLIO
15.5.5 RECENT DEVELOPMENT
15.6 ACCUBIOTECH CO LTD
15.6.1 COMPANY SNAPSHOT
15.6.2 PRODUCT PORTFOLIO
15.6.3 RECENT DEVELOPMENT
15.7 ACCUQUIK TEST KITS
15.7.1 COMPANY SNAPSHOT
15.7.2 PRODUCT PORTFOLIO
15.7.3 RECENT DEVELOPMENT
15.8 AIDIAN
15.8.1 COMPANY PROFILE
15.8.2 PRODUCT PORTFOLIO
15.8.3 RECENT DEVELOPMENT
15.9 ALFA SCIENTIFIC DESIGNS, INC.
15.9.1 COMPANY SNAPSHOT
15.9.2 PRODUCT PORTFOLIO
15.9.3 RECENT DEVELOPMENT
15.1 APACOR LIMITED
15.10.1 COMPANY SNAPSHOT
15.10.2 PRODUCT PORTFOLIO
15.10.3 RECENT DEVELOPMENT
15.11 BIOPANDA REAGENTS LTD
15.11.1 COMPANY SNAPSHOT
15.11.2 PRODUCT PORTFOLIO
15.11.3 RECENT DEVELOPMENT
15.12 BODITECH MED INC.
15.12.1 COMPANY SNAPSHOT
15.12.2 PRODUCT PORTFOLIO
15.12.3 RECENT DEVELOPMENT
15.13 CENOGENICS CORPORATION
15.13.1 COMPANY SNAPSHOT
15.13.2 PRODUCT PORTFOLIO
15.13.3 RECENT DEVELOPMENT
15.14 CERTEST BIOTEC.
15.14.1 COMPANY SNAPSHOT
15.14.2 PRODUCT PORTFOLIO
15.14.3 RECENT DEVELOPMENT
15.15 CTK BIOTECH, INC.
15.15.1 COMPANY SNAPSHOT
15.15.2 PRODUCT PORTFOLIO
15.15.3 RECENT DEVELOPMENT
15.16 EDP BIOTECH
15.16.1 COMPANY SNAPSHOT
15.16.2 PRODUCT PORTFOLIO
15.16.3 1.16.3 RECENT DEVELOPMENT
15.17 EPITOPE DIAGNOSTICS, INC.
15.17.1 COMPANY SNAPSHOT
15.17.2 PRODUCT PORTFOLIO
15.17.3 RECENT DEVELOPMENT
15.18 EUROLYSER DIAGNOSTICA GMBH
15.18.1 COMPANY SNAPSHOT
15.18.2 PRODUCT PORTFOLIO
15.18.3 RECENT DEVELOPMENT
15.19 FIRSTEP
15.19.1 COMPANY SNAPSHOT
15.19.2 PRODUCT PORTFOLIO
15.19.3 RECENT DEVELOPMENT
15.2 HANGZHOU CLONGENE BIOTECH CO., LTD
15.20.1 COMPANY SNAPSHOT
15.20.2 PRODUCT PORTFOLIO
15.20.3 RECENT DEVELOPMENT
15.21 HUMASIS.COM
15.21.1 COMPANY SNAPSHOT
15.21.2 PRODUCT PORTFOLIO
15.21.3 RECENT DEVELOPMENT
15.22 JANT PHARMACAL CORPORATION
15.22.1 COMPANY SNAPSHOT
15.22.2 PRODUCT PORTFOLIO
15.22.3 RECENT DEVELOPMENT
15.23 PRIMA LAB SA
15.23.1 COMPANY SNAPSHOT
15.23.2 PRODUCT PORTFOLIO
15.23.3 RECENT DEVELOPMENT
15.24 ULTI MED PRODUCTS (DEUTSCHLAND) GMBH
15.24.1 COMPANY SNAPSHOT
15.24.2 PRODUCT PORTFOLIO
15.24.3 RECENT DEVELOPMENT
16 QUESTIONNAIRE
17 RELATED REPORTS
TABLE 1 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 2 NORTH AMERICA LATERAL FLOW IMMUNO-FOB TEST KITS IN FECAL OCCULT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 3 NORTH AMERICA IMMUNO-FOB AGGLUTINATION TEST KITS IN FECAL OCCULT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 4 NORTH AMERICA IMMUNO-FOB ELISA TEST KITS IN FECAL OCCULT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 5 NORTH AMERICA GUAIAC FOB STOOL TEST IN FECAL OCCULT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 6 NORTH AMERICA GUAIAC FOB STOOL TEST IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 7 NORTH AMERICA KITS IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 8 NORTH AMERICA GUAIAC SLIDES IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 9 NORTH AMERICA ALPHA GUAIACONIC ACID (GUAIAC) IMPREGNATED PAPER IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 10 NORTH AMERICA SENSITIVITY IS 50NG/ML IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 11 NORTH AMERICA SENSITIVITY IS 75NG/ML IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 12 NORTH AMERICA REAGENTS IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 13 NORTH AMERICA FLUSHABLE REAGENT PAD OR TISSUE IN FECAL OCCULT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 NORTH AMERICA OTHERS IN FECAL OCCULT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 15 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 16 NORTH AMERICA COLORECTAL CANCER SCREENING IN FECAL OCCULT BLOOD TESTS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 17 NORTH AMERICA COLORECTAL CANCER SCREENING IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 18 NORTH AMERICA CONCERN FOR GASTROINTESTINAL BLEEDING IN FECAL OCCULT BLOOD TESTS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 19 NORTH AMERICA CONCERN FOR GASTROINTESTINAL BLEEDING IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 20 NORTH AMERICA POYLPS IN FECAL OCCULT BLOOD TESTS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 21 NORTH AMERICA POLYPS IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 22 NORTH AMERICA DIVERTICULOSIS IN FECAL OCCULT BLOOD TESTS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 23 NORTH AMERICA DIVERTICULOSIS IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 24 NORTH AMERICA ULCERS IN FECAL OCCULT BLOOD TESTS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 25 NORTH AMERICA ULCERS IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 26 NORTH AMERICA HAEMORRHOIDS IN FECAL OCCULT BLOOD TESTS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 27 NORTH AMERICA HEMORRHOIDS IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 28 NORTH AMERICA COLITIS IN FECAL OCCULT BLOOD TESTS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 29 NORTH AMERICA COLITIS IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 30 NORTH AMERICA ANEMIA IN FECAL OCCULT BLOOD TESTS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 31 NORTH AMERICA ANEMIA IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 32 NORTH AMERICA OTHERS IN FECAL OCCULT BLOOD TESTS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 33 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 34 NORTH AMERICA DIAGNOSTIC LABORATORIES IN FECAL OCCULT BLOOD TESTS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 35 NORTH AMERICA HOSPITALS IN FECAL OCCULT BLOOD TESTS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 36 NORTH AMERICA SPECIALITY CLINICS IN FECAL OCCULT BLOOD TESTS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 37 NORTH AMERICA OTHERS IN FECAL OCCULT BLOOD TESTS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 38 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 39 NORTH AMERICA DIRECT TENDER IN FECAL OCCULT BLOOD TESTS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 40 NORTH AMERICA RETAIL SALE IN FECAL OCCULT BLOOD TESTS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 41 NORTH AMERICA RETAIL SALE IN FECAL OCCULT BLOOD TESTS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 42 NORTH AMERICA OTHERS IN FECAL OCCULT BLOOD TESTS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 43 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 44 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 45 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)
TABLE 46 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)
TABLE 47 NORTH AMERICA GUAIAC FOB STOOL TEST IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 48 NORTH AMERICA GUAIAC FOB STOOL TEST IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)
TABLE 49 NORTH AMERICA GUAIAC FOB STOOL TEST IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)
TABLE 50 NORTH AMERICA KITS IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 51 NORTH AMERICA KITS IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)
TABLE 52 NORTH AMERICA KITS IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)
TABLE 53 NORTH AMERICA GUAIAC SLIDES IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 54 NORTH AMERICA GUAIAC SLIDES IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)
TABLE 55 NORTH AMERICA GUAIAC SLIDES IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)
TABLE 56 NORTH AMERICA ALPHA GUAIACONIC ACID (GUAIAC) IMPREGNATED PAPER IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 57 NORTH AMERICA ALPHA GUAIACONIC ACID (GUAIAC) IMPREGNATED PAPER IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)
TABLE 58 NORTH AMERICA ALPHA GUAIACONIC ACID (GUAIAC) IMPREGNATED PAPER IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)
TABLE 59 NORTH AMERICA SENSITIVITY IS 50NG/ML IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 60 NORTH AMERICA SENSITIVITY IS 50NG/ML IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)
TABLE 61 NORTH AMERICA SENSITIVITY IS 50NG/ML IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)
TABLE 62 NORTH AMERICA SENSITIVITY IS 75NG/ML IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 63 NORTH AMERICA SENSITIVITY IS 75NG/ML IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)
TABLE 64 NORTH AMERICA SENSITIVITY IS 75NG/ML IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)
TABLE 65 NORTH AMERICA REAGENTS IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 66 NORTH AMERICA REAGENTS IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)
TABLE 67 NORTH AMERICA REAGENTS IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)
TABLE 68 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 69 NORTH AMERICA COLORECTAL CANCER SCREENING IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 70 NORTH AMERICA CONCERN FOR GASTROINTESTINAL BLEEDING IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 71 NORTH AMERICA POLYPS IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 72 NORTH AMERICA DIVERTICULOSIS IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 73 NORTH AMERICA ULCERS IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 74 NORTH AMERICA HAEMORRHOIDS IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 75 NORTH AMERICA COLITIS IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 76 NORTH AMERICA ANEMIA IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 77 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 78 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 79 U.S. FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 80 U.S. FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)
TABLE 81 U.S. FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)
TABLE 82 U.S. GUAIAC FOB STOOL TEST IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 83 U.S. GUAIAC FOB STOOL TEST IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)
TABLE 84 U.S. GUAIAC FOB STOOL TEST IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)
TABLE 85 U.S. KITS IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 86 U.S. KITS IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)
TABLE 87 U.S. KITS IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)
TABLE 88 U.S. GUAIAC SLIDES IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 89 U.S. GUAIAC SLIDES IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)
TABLE 90 U.S. GUAIAC SLIDES IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)
TABLE 91 U.S. ALPHA GUAIACONIC ACID (GUAIAC) IMPREGNATED PAPER IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 92 U.S. ALPHA GUAIACONIC ACID (GUAIAC) IMPREGNATED PAPER IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)
TABLE 93 U.S. ALPHA GUAIACONIC ACID (GUAIAC) IMPREGNATED PAPER IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)
TABLE 94 U.S. SENSITIVITY IS 50NG/ML IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 95 U.S. SENSITIVITY IS 50NG/ML IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)
TABLE 96 U.S. SENSITIVITY IS 50NG/ML IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)
TABLE 97 U.S. SENSITIVITY IS 75NG/ML IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 98 U.S. SENSITIVITY IS 75NG/ML IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)
TABLE 99 U.S. SENSITIVITY IS 75NG/ML IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)
TABLE 100 U.S. REAGENTS IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 101 U.S. REAGENTS IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)
TABLE 102 U.S. REAGENTS IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)
TABLE 103 U.S. FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 104 U.S. COLORECTAL CANCER SCREENING IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 105 U.S. CONCERN FOR GASTROINTESTINAL BLEEDING IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 106 U.S. POLYPS IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 107 U.S. DIVERTICULOSIS IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 108 U.S. ULCERS IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 109 U.S. HAEMORRHOIDS IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 110 U.S. COLITIS IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 111 U.S. ANEMIA IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 112 U.S. FECAL OCCULT BLOOD TESTS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 113 U.S. FECAL OCCULT BLOOD TESTS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 114 CANADA FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 115 CANADA FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)
TABLE 116 CANADA FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)
TABLE 117 CANADA GUAIAC FOB STOOL TEST IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 118 CANADA GUAIAC FOB STOOL TEST IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)
TABLE 119 CANADA GUAIAC FOB STOOL TEST IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)
TABLE 120 CANADA KITS IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 121 CANADA KITS IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)
TABLE 122 CANADA KITS IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)
TABLE 123 CANADA GUAIAC SLIDES IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 124 CANADA GUAIAC SLIDES IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)
TABLE 125 CANADA GUAIAC SLIDES IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)
TABLE 126 CANADA ALPHA GUAIACONIC ACID (GUAIAC) IMPREGNATED PAPER IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 127 CANADA ALPHA GUAIACONIC ACID (GUAIAC) IMPREGNATED PAPER IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)
TABLE 128 CANADA ALPHA GUAIACONIC ACID (GUAIAC) IMPREGNATED PAPER IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)
TABLE 129 CANADA SENSITIVITY IS 50NG/ML IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 130 CANADA SENSITIVITY IS 50NG/ML IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)
TABLE 131 CANADA SENSITIVITY IS 50NG/ML IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)
TABLE 132 CANADA SENSITIVITY IS 75NG/ML IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 133 CANADA SENSITIVITY IS 75NG/ML IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)
TABLE 134 CANADA SENSITIVITY IS 75NG/ML IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)
TABLE 135 CANADA REAGENTS IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 136 CANADA REAGENTS IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)
TABLE 137 CANADA REAGENTS IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)
TABLE 138 CANADA FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 139 CANADA COLORECTAL CANCER SCREENING IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 140 CANADA CONCERN FOR GASTROINTESTINAL BLEEDING IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 141 CANADA POLYPS IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 142 CANADA DIVERTICULOSIS IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 143 CANADA ULCERS IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 144 CANADA HAEMORRHOIDS IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 145 CANADA COLITIS IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 146 CANADA ANEMIA IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 147 CANADA FECAL OCCULT BLOOD TESTS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 148 CANADA FECAL OCCULT BLOOD TESTS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 149 MEXICO FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 150 MEXICO FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)
TABLE 151 MEXICO FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)
TABLE 152 MEXICO GUAIAC FOB STOOL TEST IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 153 MEXICO GUAIAC FOB STOOL TEST IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)
TABLE 154 MEXICO GUAIAC FOB STOOL TEST IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)
TABLE 155 MEXICO KITS IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 156 MEXICO KITS IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)
TABLE 157 MEXICO KITS IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)
TABLE 158 MEXICO GUAIAC SLIDES IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 159 MEXICO GUAIAC SLIDES IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)
TABLE 160 MEXICO GUAIAC SLIDES IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)
TABLE 161 MEXICO ALPHA GUAIACONIC ACID (GUAIAC) IMPREGNATED PAPER IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 162 MEXICO ALPHA GUAIACONIC ACID (GUAIAC) IMPREGNATED PAPER IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)
TABLE 163 MEXICO ALPHA GUAIACONIC ACID (GUAIAC) IMPREGNATED PAPER IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)
TABLE 164 MEXICO SENSITIVITY IS 50NG/ML IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 165 MEXICO SENSITIVITY IS 50NG/ML IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)
TABLE 166 MEXICO SENSITIVITY IS 50NG/ML IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)
TABLE 167 MEXICO SENSITIVITY IS 75NG/ML IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 168 MEXICO SENSITIVITY IS 75NG/ML IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)
TABLE 169 MEXICO SENSITIVITY IS 75NG/ML IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)
TABLE 170 MEXICO REAGENTS IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 171 MEXICO REAGENTS IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)
TABLE 172 MEXICO REAGENTS IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)
TABLE 173 MEXICO FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 174 MEXICO COLORECTAL CANCER SCREENING IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 175 MEXICO CONCERN FOR GASTROINTESTINAL BLEEDING IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 176 MEXICO POLYPS IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 177 MEXICO DIVERTICULOSIS IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 178 MEXICO ULCERS IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 179 MEXICO HAEMORRHOIDS IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 180 MEXICO COLITIS IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 181 MEXICO ANEMIA IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 182 MEXICO FECAL OCCULT BLOOD TESTS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 183 MEXICO FECAL OCCULT BLOOD TESTS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
FIGURE 1 NORTH AMERICA FECAL OCCULT BLOOD TESTSMARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 NORTH AMERICA FECAL OCCULT BLOOD TESTSMARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET: SEGMENTATION
FIGURE 11 RISING CASES OF COLORECTAL CANCER NORTH AMERICALY AND EASY AVAILABILITY OF FECAL OCCULT IMMUNOLOGICAL TEST DEVICES IN ONLINE STORES ARE EXPECTED TO DRIVE THE GROWTH OF THE NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET FROM 2023 TO 2030
FIGURE 12 THE LATERAL FLOW IMMUNO-FOB, TEST KITS SEGMENT, IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET IN 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET
FIGURE 14 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET: BY TEST TYPE, 2022
FIGURE 15 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION)
FIGURE 16 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET: BY TEST TYPE, CAGR (2023-2030)
FIGURE 17 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET: BY TEST TYPE, LIFELINE CURVE
FIGURE 18 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET: BY APPLICATION, 2022
FIGURE 19 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET: BY APPLICATION, 2023-2030 (USD MILLION)
FIGURE 20 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET: BY APPLICATION, CAGR (2023-2030)
FIGURE 21 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 22 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET: BY END USER, 2022
FIGURE 23 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 24 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 25 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET : BY END USER, LIFELINE CURVE
FIGURE 26 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET : BY DISTRIBUTION CHANNEL, 2022
FIGURE 27 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET : BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
FIGURE 28 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET : BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 29 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 30 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET: SNAPSHOT (2022)
FIGURE 31 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET: BY COUNTRY (2022)
FIGURE 32 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 33 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 34 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET: BY TEST TYPE (2023-2030)
FIGURE 35 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET: COMPANY SHARE 2022 (%)
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.